Ofatumumab and Relapsed CLL
Interim results from PROLONG, an open-label, two-arm phase III randomised study that compared ofatumumab versus observation in patients in remission following induction treatment for relapsed chronic lymphocytic leukaemia, were presented at the 2014 American Society of Hematology annual meeting.
Patients (n = 474) from Europe and the USA were randomised prior to the interim analysis. The median progression-free survival – the primary end point – was 28.6 months for ofatumumab and 15.2 months for observation (HR = 0.48; p<0.0001). Those receiving ofatumumab had a significantly longer time to the start of the next treatment compared with those in the observation arm (median 38.0 vs. 27.4 months, HR = 0.63; p = 0.0076).
Click here for the full article.